TY - JOUR T1 - Clinical Predictors for Neutrophil–to–Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment JF - In Vivo JO - In Vivo SP - 723 LP - 729 VL - 31 IS - 4 AU - PUO-HSIEN LE AU - KUNG-HAO LIANG AU - MING-LING CHANG AU - CHAO-WEI HSU AU - YI-CHENG CHEN AU - CHIH-LANG LIN AU - WEY-RAN LIN AU - MING-WEI LAI AU - CHAU-TING YEH Y1 - 2017/07/01 UR - http://iv.iiarjournals.org/content/31/4/723.abstract N2 - Background: A lower neutrophil–to–lymphocyte ratio (NLR) was found to be associated with better clinical outcomes in hepatitis B-related liver cirrhosis and hepatocellular carcinoma. We aimed to identify pre-therapeutic variables capable of predicting NLR changes in patients with hepatitis B receiving peginterferon therapy. Patients and Methods: The baseline clinicopathological data were analyzed to correlate with NLR changes before and 1 year after peginterferon treatment in 71 patients with hepatitis B. Results: Univariate analysis revealed that pre-treatment NLR itself negatively predicted NLR changes following peginterferon treatment (odds ratio(OR)=0.320, p=0.013). Further analysis identified pre-treatment NLR, hemoglobin and hepatitis B surface antigen level as independent predictors for NLR changes (adjusted p=0.028, 0.005, and 0.028, respectively). A predictive score composed of these three factors had an area under the curve of 76.5% (p<0.001). Conclusion: Pretreatment NLR, hemoglobin and hepatitis B surface antigen level in combination, effectively predicted NLR changes following peginterferon treatment. ER -